Worth reading
54Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Details of issuance or disposal
18th to 20th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clauses)
Specific use of funds
Development expenses for RBM-007 for the treatment of achondroplasiaAmount 2,548 (¥ million) / Scheduled timing of expenditures April 2026 to March 2029
Working capitalAmount 876 (¥ million) / Scheduled timing of expenditures April 2026 to March 2029
Terms of the stock acquisition rights
Exercise price
Only the existence of an exercise price adjustment clause is stated. The specific initial exercise price and adjustment floor are not disclosed.
Most recent equity financing
Timing Disclosure dated 23 July 2025 / Type 18th to 20th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clauses) / Amount Not disclosed
Impact on Business Performance
This transaction will have no impact on results for the fiscal year ending March 2026.
| Item | Details |
|---|---|
| Type of issuance or disposal | 18th to 20th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clauses) |
| Specific use of funds | Details Development expenses for RBM-007 for the treatment of achondroplasia / Amount 2,548 (¥ million) / Scheduled timing of expenditures April 2026 to March 2029, Details Working capital / Amount 876 (¥ million) / Scheduled timing of expenditures April 2026 to March 2029 |
| Exercise price | Only the existence of an exercise price adjustment clause is stated. The specific initial exercise price and adjustment floor are not disclosed. |
| Most recent equity financing | Timing Disclosure dated 23 July 2025 / Type 18th to 20th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clauses) / Amount Not disclosed |
| Impact on Business Performance | This transaction will have no impact on results for the fiscal year ending March 2026. |
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following consideration of the development strategy, including consultations with the PMDA, it was determined that the Company could proceed directly to a Phase 3 clinical trial. In parallel with the Phase 3 clinical trial, the Company also plans to systematically obtain the nonclinical trial data required for regulatory approval, with the aim of facilitating the regulatory approval process and improving the certainty of the overall development program.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.